Ashland (ASH) reports Q1 earnings: What key metrics have to say
|Ashland (ASH) reported $386 million in revenue for the quarter ended December 2025, representing a year-over-year decline of 4.7%. EPS of $0.26 for the same period compares to $0.28 a year ago.
The reported revenue represents a surprise of -5.47% over the Zacks Consensus Estimate of $408.33 million. With the consensus EPS estimate being $0.23, the EPS surprise was +12.46%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Ashland performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Intermediates: $31 million versus the three-analyst average estimate of $30.26 million. The reported number represents a year-over-year change of -6.1%.
- Revenue- Life Sciences: $139 million versus the three-analyst average estimate of $145.72 million. The reported number represents a year-over-year change of +3.7%.
- Revenue- Personal care: $123 million versus $131.71 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -8.2% change.
- Revenue- Specialty Additives: $102 million versus the three-analyst average estimate of $110.58 million. The reported number represents a year-over-year change of -11.3%.
- Revenue- Intersegment sales: $-9 million versus $-10 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -18.2% change.
- Adjusted EBITDA- Life Science: $31 million compared to the $32.29 million average estimate based on three analysts.
- Adjusted EBITDA- Personal care: $26 million versus the three-analyst average estimate of $26.78 million.
- Adjusted EBITDA- Specialty additives: $15 million compared to the $15.65 million average estimate based on three analysts.
- Adjusted EBITDA- Intermediates: $1 million versus $2.05 million estimated by three analysts on average.
- OPERATING INCOME- Unallocated and other: $-26 million compared to the $-17.25 million average estimate based on two analysts.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.